We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Thermo Fisher Partners with Wuxi Diagnostics and Mayo Clinic for Developing New COVID-19 Serology Test

By HospiMedica International staff writers
Posted on 15 May 2020
Print article
Illustration
Illustration
Thermo Fisher Scientific Inc. (Waltham, MA, USA) will be developing a total antibodies test in collaboration with Wuxi Diagnostics (Shanghai, China) and Mayo Clinic (Rochester, NY, USA).

The new Thermo Scientific OmniPath COVID-19 Total Antibody ELISA test is the result of ongoing collaboration between the three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher will seek US FDA Emergency Use Authorization (EUA) and international regulatory authorizations for the test over the next few weeks. Once approved for use, the test will detect Immunoglobulin M (IgM) and Immunoglobulin G (IgG) to help clinicians determine if a patient has been exposed to SARS-CoV-2. The test is designed to run on an open instrument platform, and the determination of antibody status will aid in the diagnosis of the disease during the acute and recovery stages of infection. Thermo Fisher will begin manufacturing the Thermo Scientific OmniPath COVID-19 Total Antibody ELISA test at its sites in the US and Europe in the next few weeks as it prepares to submit for EUA.

“Stopping the spread of COVID-19 requires comprehensive testing solutions, and we are very pleased to join forces with WuXi Diagnostics and Mayo Clinic to respond to the widespread need for antibody-based tests,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “Working together, we will now be able to provide governments, healthcare systems and communities with yet another important tool to aid in the fight against the pandemic.”

“We are pleased to join forces with Thermo Fisher and Mayo Clinic in the battle against the pandemic,” said Jason Liu, Ph.D., chief executive officer of WuXi Diagnostics. “This global collaboration of R&D, clinical expertise, manufacturing and commercialization capability will significantly advance serological testing for COVID-19. WuXi Diagnostics offers an open-access platform for innovative diagnostic solutions. By collaborating with our partners, we're dedicated to supporting healthcare professionals and their patients around the world.”

“Rapidly expanding access to high-quality testing requires bold collaborations across the laboratory industry,” said Gianrico Farrugia, M.D., chief executive officer and president of Mayo Clinic. “This marks a significant milestone in our national testing response to COVID-19 and was made possible by bringing together the commercialization capabilities of Thermo Fisher Scientific, testing development abilities of WuXi Diagnostics, and clinical and laboratory expertise of Mayo Clinic physicians and scientists.”


Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Neonatal Ventilator
Servo-n

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.